Analysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience

Simple item page
dc.contributor.authorSarmiento, M.
dc.contributor.authorSalinas, J.
dc.contributor.authorRojas, P.
dc.contributor.authorGutierrez, C.
dc.contributor.authorVidal, M.
dc.contributor.authorJara, V
dc.contributor.authorGarcia, M. J.
dc.contributor.authorCampbell, M. J.
dc.contributor.authorFlores, Y.
dc.contributor.authorSandoval, V
dc.contributor.authorVergara, M.
dc.contributor.authorPalacios, F.
dc.contributor.authorOcqueteau, M.
dc.date.accessioned2025-01-20T16:11:10Z
dc.date.available2025-01-20T16:11:10Z
dc.date.issued2024
dc.description.abstractAdequate stem cell harvesting is required for autologous hematopoietic transplantation. In deficient mobilizer patients, the collection of stem cells can be challenging because of the impossibility of achieving satisfactory CD34 cell counts with GCSF + - chemotherapy. Plerixafor is a potent and expensive drug that promotes the release of stem cells from the medullary niche to the peripheral blood and allows satisfactory harvests. We performed a retrospective analysis of 370 patients with myeloma and lymphoma harvested at our institution. 99 % of patients achieved satisfactory apheresis using Plerixafor in 45 %. Satisfactory harvests were obtained in patients mobilized with GCSF or plerixafor. In patients who used plerixafor, it was necessary to perform fewer apheresis procedures (P = 0.05). In multivariate analysis, the only factor that predicted the need for plerixafor was the presence of less than 30,000 CD34 / ul on the day of apheresis (OR 0.3. p < 0.001). Since we adopted the plerixafor protocol guided by CD34 counts, the number of patients with harvest failure has decreased. In conclusion, the rational and standardized use of plerixafor favors satisfactory harvest in patients who require autologous transplantation in South-American patients.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.transci.2024.103983
dc.identifier.eissn1878-1683
dc.identifier.issn1473-0502
dc.identifier.urihttps://doi.org/10.1016/j.transci.2024.103983
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90254
dc.identifier.wosidWOS:001289185900001
dc.issue.numero5
dc.language.isoen
dc.revistaTransfusion and apheresis science
dc.rightsacceso restringido
dc.subjectAutologous hematopoietic stem cell
dc.subjecttransplantation
dc.subjectPlerixafor
dc.subjectMultiple myeloma
dc.subjectLymphoma
dc.subjectGCSF
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAnalysis of apheresis outcomes in a cohort of Chilean patients treated with autologous stem cell transplantation: A single center real-world experience
dc.typeartículo
dc.volumen63
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas